MONOCLONAL ANTIBODY THERAPEUTICS MARKET ANALYSIS

The global monoclonal antibody therapeutics market is estimated to be valued at US$ 205.39 billion in 2023 and is expected to exhibit a CAGR of 12.69% during the forecast period (2023-2030).

Analysts’ Views on Global Monoclonal Antibody Therapeutics Market:

The global monoclonal antibody therapeutics market's growth can be hindered by disadvantages associated with the use of monoclonal antibodies. Implementation of monoclonal antibody therapeutics for the treatment of various disease, is expected to drive the global monoclonal antibody therapeutics market growth over the forecast period. For instance, in July 2020, a report published by National Center for Biotechnology Information (NCBI), stated that monoclonal antibody therapy has recently become one of the major modalities for the treatment of cancer.

Figure 1. Global Monoclonal Antibody Therapeutics Market Share (%), By Source, 2023

To learn more about this report, Request sample copy

Global Monoclonal Antibody Therapeutics Market – Driver

Increasing prevalence of infectious diseases  

Increasing prevalence of infectious diseases needs the use of monoclonal antibody therapeutics for treatment which, is expected to drive the monoclonal antibody therapeutics market over the forecast period. For instance, on 25 January 2023, according to a report published by Centers for Disease Control and Prevention (CDC), stated that the number of emergency department visits with infectious diseases as the primary diagnosis was 3.2 million respectively.

Figure 2. Global Monoclonal Antibody Therapeutics Market Value (US$ Billion), By Region, 2023

To learn more about this report, Request sample copy

Global Monoclonal Antibody Therapeutics Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global monoclonal antibody therapeutics market over the forecast period. North America holds 45.1% of the market share due to the increasing prevalence of autoimmune diseases in the region. According to the data published by the National Institute of Health, in April 2020, 41 million people were diagnosed with autoimmune diseases from past 10 years.

Global Monoclonal Antibody Therapeutics Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

The COVID-19 pandemic affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a positive impact on the global monoclonal antibody therapeutics market. For instance, in August 2020, the National Institutes of Health (NIH), announced the start of two clinical trials for a potential coronavirus treatment called monoclonal antibodies.

Global Monoclonal Antibody Therapeutics Market Segmentation:

The global monoclonal antibody therapeutics market report is segmented into Source, Application, Distribution Channel, and Region

Based on Source, the market is segmented into human, chimeric, murine, and humanized. Out of which, the humanized segment is expected to hold a dominant position in the monoclonal antibody therapeutics market during the forecast period and this is attributed to the increasing usage of humanized monoclonal antibody therapeutics for the treatment of cancer.

Based on Application, the market is segmented into cancer, autoimmune disease, hematological disease, infectious disease, and others. Out of which, the cancer segment is expected to hold a dominant position in the monoclonal antibody therapeutics market during the forecast period and this is attributed to the increasing prevalence of cancer.

Based on Distribution Channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. Out of which, the hospital pharmacy segment is expected to dominate the market over the forecast period and this is attributed to the increase in the number of new hospitals for the management of cancer and other autoimmune diseases over the forecast period.

Among all segmentation, the application segment has the highest potential due to the increasing prevalence of autoimmune diseases over the forecast period. For instance, in May 2020, according to a report published on National Center for Biotechnology Information (NCBI), autoimmune diseases affect 20% of the total human population in the world.

Global Monoclonal Antibody Therapeutics Market Cross Sectional Analysis:

In source segment, humanized segment holds a dominant segment in the North America region due to the increasing use of humanized monoclonal antibody therapeutics. For instance, in February 2022, according to a report published by National Center for Biotechnology Information (NCBI), humanized monoclonal antibodies can be used for targeting hypoxic human tumors.

Global Monoclonal Antibody Therapeutics Market: Key Developments

• Effective use of monoclonal antibody therapeutics for the treatment of various diseases is expected to drive the global monoclonal antibody therapeutics market growth over the forecast period
• In August 2020, Novartis AG, a manufacturer of pharmaceuticals, announced that the U.S. Food and Drugs Administration (FDA) approved Kesimpta as an injection for subcutaneous use for the treatment of relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
• In May 2021, Novartis AG, a manufacturer of pharmaceuticals, and Molecular Partners, a clinical-stage biopharmaceutical company, announced the start of the clinical trial EMPATHY, a Phase 2 and 3 study, to explore the use of its novel DARPin therapeutic candidate ensovibep (MP0420) for the treatment of COVID-19
• In January 2021, Sanofi, a multinational pharmaceutical and healthcare company, announced the acquisition of Kymab, a clinical-stage biopharmaceutical company to adding KY1005, a human monoclonal antibody targeting key immune system regulator OX40L, to its pipeline
• In October 2020, International AIDS Vaccine Initiative, a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, and Serum Institute of India Pvt. Ltd., a leading manufacturer of vaccines and biologics, announced an agreement with Merck KGaA, a leading science and technology company, to develop SARS-CoV-2 neutralizing monoclonal antibodies (mAbs) co-invented by International AIDS Vaccine Initiative and Scripps Research as innovative interventions to address the COVID-19 pandemic.

Global Monoclonal Antibody Therapeutics Market: Key Trends

Increasing prevalence of diseases and factors associated with monoclonal antibody therapeutics to drive the market growth over the forecast period

Increasing prevalence of autoimmune disease needs effective factors for the treatment of autoimmune disease is expected to drive the monoclonal antibody therapeutics  market growth over the forecast period. For instance, in November 2022, according to a report published by ScienceDirect, a scientific journal, the prevalence of autoimmunity and autoimmune diseases is increasing and requires an urgent call to action for improved understanding, diagnosis, treatment, and prevention of autoimmune disease.

Global Monoclonal Antibody Therapeutics Market: Restraint

Side effects of using monoclonal antibody therapeutics

The global monoclonal antibody therapeutics market can be hindered by side effects associated with the use of monoclonal antibody therapeutics. For instance, in November 2022, according to an article published by American Cancer Society, Inc., a nationwide voluntary health organization dedicated to eliminating cancer, stated Bevacizumab (Avastin), an monoclonal antibody that targets a protein called vascular endothelial growth factor (VEGF) that affects tumor blood vessel growth. It can cause side effects such as high blood pressure, bleeding, poor wound healing, blood clots, and kidney damage.

Therefore, improved monoclonal antibody therapeutics with lesser side effects may help in increasing the wider application of monoclonal antibody therapeutics and can tackle these restraints.

Global Monoclonal Antibody Therapeutics Market - Key Players

Major players operating in the global monoclonal antibody therapeutics market include Pfizer Inc., Novartis AG, Bayer AG, Sanofi, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Merck KGaA, GSK plc., AbbVie Inc., Bristol-Myers Squibb Company, Regeneron Pharmaceuticals Inc., AstraZeneca, AbCellera Biologics Inc., Molecular Depot LLC, DAIICHI SANKYO COMPANY, LIMITED., Abbott, Biogen, Thermo Fisher Scientific, Inc., Cell Signaling Technology, Inc, Intas Pharmaceuticals Ltd., Avantor Inc., UCB S.A., Merus N.V., GENEXTGENOMICS.COM, Biogenuix.